Internal Medicine, Rheumatology · Aventura, FL
NPI
1619388840
Since 2014
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2801 NE 213th St Ste 801
Aventura, FL, 33180
Phone (305) 932-0124
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
100,988 services
Medicare patients, 2024
359
Average age 77
Drug cost, 2024
$5.5M
3,267 prescriptions
Company payments, 2025
$1,165
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ronald Yglesias was code J3111 (injection, romosozumab-aqqg, 1 mg), 32,971 times for 43 patients. In total Ronald Yglesias billed 100,988 services in 72 codes, and Medicare paid $1.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 32,971 | 43 | $8.37 | $276K |
| J3262 Injection, tocilizumab, 1 mg | Office | 20,524 | 13 | $4.72 | $97K |
| J0897 Injection, denosumab, 1 mg | Office | 12,300 | 137 | $20.53 | $253K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 1,410 | 13 | $24.94 | $35K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,325 | 27 | $0.10 | $135 |
| 99214 Office E&M - Established | Office | 501 | 251 | $98.51 | $49K |
| 96401 Chemotherapy Administration | Office | 413 | 104 | $55.61 | $23K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 138 | 30 | $0.09 | $12.47 |
| 96413 Chemotherapy Administration | Office | 119 | 44 | $100.55 | $12K |
| 77080 Standard X-ray | Office | 111 | 110 | $39.76 | $4,413 |
| 96415 Chemotherapy Administration | Office | 96 | 24 | $21.47 | $2,061 |
| 99204 Office E&M - New | Office | 84 | 84 | $129.60 | $11K |
| 20611 Joint Injection | Office | 46 | 29 | $88.07 | $4,051 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 43 | 37 | $13.70 | $589 |
| 96521 Chemotherapy | Office | 40 | 19 | $101.98 | $4,079 |
By year: 2022 $1.0M for 103,058 services; 2023 $1.2M for 112,571 services; 2024 $1.1M for 100,988 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 87811 Immunoassay | 43 | 21 | $40.95 | $1,761 |
Medicare prescription drug claims, 2024
In 2024, the drug Ronald Yglesias prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 373 prescriptions and refills. In total Ronald Yglesias wrote 3,267 Medicare prescriptions that cost $5.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 373 | 793 | 97 | $8,906 |
| Methotrexate Methotrexate Sodium | 340 | 656 | 105 | $6,447 |
| Prednisone Generic | 250 | 460 | 82 | $1,540 |
| Prolia Denosumab | 213 | 1,275 | 146 | $366K |
| Folic Acid Generic | 166 | 361 | 58 | $795 |
| Rinvoq Upadacitinib | 162 | 172 | 24 | $1.1M |
| Alendronate Sodium Generic | 96 | 217 | 31 | $446 |
| Diclofenac Sodium Generic | 85 | 126 | 36 | $1,819 |
| Gabapentin Generic | 77 | 146 | 18 | $986 |
| Meloxicam Generic | 77 | 142 | 37 | $435 |
| Methylprednisolone Generic | 68 | 93 | 48 | $726 |
| Leflunomide Generic | 59 | 151 | 22 | $2,164 |
| Xeljanz Xr Tofacitinib Citrate | 58 | 62 | Under 11 | $355K |
| Ibuprofen Generic | 58 | 84 | 20 | $763 |
| Azathioprine Generic | 52 | 118 | 16 | $1,627 |
Brand drugs: - claims; generic drugs: 2,276 claims; opioid claims: 52.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ronald Yglesias $1,165 ($1,165 in general payments such as food, travel and fees) from 11 companies. The largest payer was Merck Sharp & Dohme LLC with $858.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 4 | $858 |
| Aurinia Pharma U.S., Inc. AUPH | 2 | $57.58 |
| Abbvie Inc. ABBV | 2 | $52.91 |
| GlaxoSmithKline, LLC. GSK | 2 | $41.11 |
| ANI Pharmaceuticals, Inc. ANIP | 1 | $32.92 |
| Pfizer Inc. PFE | 1 | $25.13 |
| Genzyme Corporation SNY | 1 | $23.17 |
| Pharming Healthcare, Inc. | 1 | $22.21 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $20.84 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $18.18 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.